Compare ALGT & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALGT | NTLA |
|---|---|---|
| Founded | 1997 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2006 | 2016 |
| Metric | ALGT | NTLA |
|---|---|---|
| Price | $82.32 | $13.12 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 20 |
| Target Price | ★ $97.00 | $20.45 |
| AVG Volume (30 Days) | 443.7K | ★ 3.7M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.62 | 27.43 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,606,579,000.00 | $67,671,000.00 |
| Revenue This Year | $5.81 | N/A |
| Revenue Next Year | $8.05 | $62.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 3.74 | ★ 16.92 |
| 52 Week Low | $39.82 | $5.90 |
| 52 Week High | $118.00 | $28.24 |
| Indicator | ALGT | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 44.05 | 49.96 |
| Support Level | $54.65 | $12.55 |
| Resistance Level | $94.50 | $14.61 |
| Average True Range (ATR) | 4.97 | 0.69 |
| MACD | -0.42 | -0.10 |
| Stochastic Oscillator | 32.74 | 35.74 |
Allegiant Travel Co is a leisure travel company focused on providing travel and leisure services and products to residents of underserved cities in the United States. It operates a low-cost, low utilization passenger airline marketed to leisure travelers in underserved cities, allowing it to sell air transportation both on a stand-alone basis and bundled with the sale of air-related and third-party services and products. In addition, it provides air transportation under fixed-fee flight arrangements. In connection with its leisure travel focus, the company has opened Sunseeker Resort Charlotte Harbor, equipped with several guestrooms and food and beverage outlets. The company's operating segments are the Airline, which generates the maximum revenue, and Sunseeker Resort.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.